Q4 2024 · 13F-HR
ACUTA CAPITAL PARTNERS, LLCholdings as filed
Filed 2025-02-14 · accession 0001104659-25-013432
$99.4M
Reported value
39
Positions
2024-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $9.5M | 9.55% | 1,111,071 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $7.2M | 7.28% | 104,800 | Common | SOLE |
| 89157D105 | TRML | TOURMALINE BIO INC | $7.1M | 7.18% | 351,842 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $6.3M | 6.32% | 122,900 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $6.0M | 6.05% | 267,368 | Common | SOLE |
| 00032Q104 | WHWK | AADI BIOSCIENCES INC | $5.8M | 5.87% | 1,849,402 | Common | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $5.2M | 5.23% | 67,500 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $4.9M | 4.92% | 111,700 | Common | SOLE |
| 04016X101 | ARGX | ARGENX SE | $4.2M | 4.28% | 6,910 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $3.7M | 3.71% | 45,000 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $3.2M | 3.20% | 771,958 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHA-ADR | $3.2M | 3.18% | 22,976 | Common | SOLE |
| 589492107 | MREO | MEREO BIOPHARMA GROUP PL-ADR | $2.7M | 2.74% | 779,308 | Common | SOLE |
| 10919W405 | DRUG | BRIGHT MINDS BIOSCIENCES INC | $2.5M | 2.50% | 69,124 | Common | SOLE |
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $2.5M | 2.49% | 447,500 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $2.3M | 2.35% | 87,658 | Common | SOLE |
| G4444H101 | BBOT | HELIX ACQUISITION CORP II | $1.9M | 1.91% | 180,945 | Common | SOLE |
| 90466Y103 | — | UNICYCIVE THERAPEUTICS INC | $1.8M | 1.84% | 2,303,000 | Common | SOLE |
| 77313F106 | RCKT | ROCKET PHARMACEUTICALS INC | $1.7M | 1.70% | 134,500 | Common | SOLE |
| 53635D202 | LQDA | LIQUIDIA CORPORATION | $1.6M | 1.63% | 137,709 | Common | SOLE |
| 59045L106 | — | MERSANA THERAPEUTICS INC | $1.6M | 1.61% | 1,120,500 | Common | SOLE |
| 877619106 | TSHA | TAYSHA GENE THERAPIES INC | $1.5M | 1.54% | 884,244 | Common | SOLE |
| 878972108 | TECX | TECTONIC THERAPEUTIC INC | $1.5M | 1.53% | 33,008 | Common | SOLE |
| 171757206 | CDTX | CIDARA THERAPEUTICS INC | $1.5M | 1.47% | 54,473 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA CO NV | $1.3M | 1.29% | 50,000 | Common | SOLE |
| 98985Y108 | ZYME | ZYMEWORKS INC | $984,394 | 0.99% | 67,240 | Common | SOLE |
| 28617K101 | ELDN | ELEDON PHARMACEUTICALS INC | $971,290 | 0.98% | 235,750 | Common | SOLE |
| 92539P101 | — | VERVE THERAPEUTICS INC | $903,528 | 0.91% | 160,200 | Common | SOLE |
| 90400D108 | RARE | ULTRAGENYX PHARMACEUTICAL INC | $883,470 | 0.89% | 21,000 | Common | SOLE |
| 375558103 | GILD | GILEAD SCIENCES INC | $845,186 | 0.85% | 9,150 | Common | SOLE |
| 03940C100 | ACLXGBX | ARCELLX INC | $823,881 | 0.83% | 10,743 | Common | SOLE |
| 800677106 | SGMO | SANGAMO THERAPEUTICS INC | $754,800 | 0.76% | 740,000 | Common | SOLE |
| 88427A107 | — | THIRD HARMONIC BIO INC | $512,442 | 0.52% | 49,800 | Common | SOLE |
| 04317A107 | ARTV | ARTIVA BIOTHERAPEUTICS INC | $443,520 | 0.45% | 44,000 | Common | SOLE |
| 34962G208 | FBRX | FORTE BIOSCIENCES INC | $411,937 | 0.41% | 18,139 | Common | SOLE |
| 221015100 | CRVS | CORVUS PHARMACEUTICALS INC | $397,542 | 0.40% | 74,307 | Common | SOLE |
| 15102K100 | CELC | CELCUITY INC | $327,250 | 0.33% | 25,000 | Common | SOLE |
| 75383L102 | RAPP | RAPPORT THERAPEUTICS INC | $290,936 | 0.29% | 16,400 | Common | SOLE |
| 67080N119 | NUVB/WS | NUVATION BIO INC -CW27 | $20,891 | 0.02% | 90,832 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.